TherapeuticsMD Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Net Income	-0.57	-2.18	-10.28	112	-172.42	Upgrade
Depreciation & Amortization	1.19	1.28	0.44	1.19	0.74	Upgrade
Asset Writedown & Restructuring Costs	0.18	1.27	0.48	-	-	Upgrade
Stock-Based Compensation	0.08	0.26	1.27	11.57	18.13	Upgrade
Other Operating Activities	-0.08	-0.13	2.45	-111.32	93.83	Upgrade
Change in Accounts Payable	0.12	0.23	-2.14	-1.21	-1.06	Upgrade
Change in Other Net Operating Assets	1.54	0.44	-15.31	-2.88	5.65	Upgrade
Operating Cash Flow	2.42	0.73	-48.14	-4.08	-142.69	Upgrade
Operating Cash Flow Growth	231.15%	-	-	-	-	Upgrade
Capital Expenditures	-	-	-	-	-0.03	Upgrade
Sale (Purchase) of Intangibles	-	-	-	-0.36	-2.19	Upgrade
Other Investing Activities	-	-	-	223.83	-	Upgrade
Investing Cash Flow	-	-	-	223.48	-2.22	Upgrade
Long-Term Debt Repaid	-	-	-	-219.43	-50	Upgrade
Net Debt Issued (Repaid)	-	-	-	-219.43	-50	Upgrade
Issuance of Common Stock	-	-	3.15	2.47	184.67	Upgrade
Other Financing Activities	-	-	-	-1.27	-5.12	Upgrade
Financing Cash Flow	-	-	3.15	-235.21	129.55	Upgrade
Net Cash Flow	2.42	0.73	-44.99	-15.81	-15.36	Upgrade
Free Cash Flow	2.42	0.73	-48.14	-4.08	-142.73	Upgrade
Free Cash Flow Growth	231.15%	-	-	-	-	Upgrade
Free Cash Flow Margin	80.21%	41.57%	-3697.46%	-5.83%	-5547.10%	Upgrade
Free Cash Flow Per Share	0.21	0.06	-4.61	-0.43	-17.93	Upgrade
Cash Interest Paid	-	-	-	13.55	25.07	Upgrade
Levered Free Cash Flow	0.3	-2.22	-33.87	38.54	-28.46	Upgrade
Unlevered Free Cash Flow	0.3	-2.22	-33.87	38.54	-28.46	Upgrade
Change in Working Capital	1.66	0.67	-17.45	-4.09	4.59	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.